Currently, there are 267.74M common shares owned by the public and among those 255.73M shares have been available to trade.
The company’s stock has a 5-day price change of -51.10% and -76.48% over the past three months. PACB shares are trading -84.20% year to date (YTD), with the 12-month market performance down to -86.06% lower. It has a 12-month low price of $1.25 and touched a high of $14.55 over the same period. PACB has an average intraday trading volume of 9.61 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -50.99%, -64.14%, and -80.87% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Pacific Biosciences of California Inc (NASDAQ: PACB) shares accounts for 101.19% of the company’s 267.74M shares outstanding.
It has a market capitalization of $422.03M and a beta (3y monthly) value of 2.01. The earnings-per-share (ttm) stands at -$1.21. Price movements for the stock have been influenced by the stock’s volatility, which stands at 23.33% over the week and 11.03% over the month.
Analysts forecast that Pacific Biosciences of California Inc (PACB) will achieve an EPS of $Pacific Biosciences of Californ for the current quarter, $1.55 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Ranpak Holdings Corp while analysts give the company a high EPS estimate of $PharmaCyte Biotech, Inc.. Comparatively, EPS for the current quarter was $Grupo Aeroportuario Del Pacific a year ago. Earnings per share for the fiscal year are expected to increase by 15.64%, and 19.24% over the next financial year. EPS should grow at an annualized rate of -1.00% over the next five years, compared to -9.76% over the past 5-year period.
Looking at the support for the PACB, a number of firms have released research notes about the stock. Goldman stated their Neutral rating for the stock in a research note on April 18, 2024, with the firm’s price target at $7-$2.50. Stephens coverage for the Pacific Biosciences of California Inc (PACB) stock in a research note released on December 14, 2023 offered a Overweight rating with a price target of $11. UBS on their part issued Buy rating on November 17, 2023.
